Wall Street Zen Downgrades USANA Health Sciences (NYSE:USNA) to Hold

USANA Health Sciences (NYSE:USNA) was downgraded by equities research analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Saturday.

A number of other research firms also recently issued reports on USNA. Zacks Research downgraded USANA Health Sciences from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, April 22nd. Weiss Ratings restated a “sell (d)” rating on shares of USANA Health Sciences in a report on Wednesday, June 24th. Two analysts have rated the stock with a Sell rating, According to MarketBeat.com, the stock has an average rating of “Sell”.

USANA Health Sciences Stock Performance

Shares of USNA stock opened at $15.43 on Friday. The firm has a market capitalization of $284.84 million, a price-to-earnings ratio of -12.75, a price-to-earnings-growth ratio of 1.70 and a beta of 0.73. USANA Health Sciences has a one year low of $14.35 and a one year high of $32.32. The company has a 50 day moving average price of $20.41 and a 200 day moving average price of $19.64.

USANA Health Sciences (NYSE:USNA) last announced its quarterly earnings data on Tuesday, August 4th. The company reported ($0.07) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.43 by ($0.50). The company had revenue of $223.27 million for the quarter, compared to analysts’ expectations of $235.00 million. USANA Health Sciences had a negative net margin of 2.43% and a positive return on equity of 3.41%. USANA Health Sciences has set its FY 2026 guidance at 0.760-0.760 EPS. As a group, equities analysts forecast that USANA Health Sciences will post 0.76 EPS for the current fiscal year.

Insider Activity

In other USANA Health Sciences news, insider Brent Neidig sold 5,002 shares of the company’s stock in a transaction that occurred on Tuesday, June 16th. The stock was sold at an average price of $19.45, for a total value of $97,288.90. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director John Turman Fleming sold 2,450 shares of the stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $17.93, for a total transaction of $43,928.50. Following the completion of the sale, the director directly owned 4,230 shares of the company’s stock, valued at $75,843.90. This trade represents a 36.68% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 13,869 shares of company stock worth $261,441. 0.82% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the company. BlackRock Inc. acquired a new stake in USANA Health Sciences during the 2nd quarter valued at $33,182,000. Pzena Investment Management LLC acquired a new position in USANA Health Sciences in the 2nd quarter worth $25,739,000. Renaissance Technologies LLC boosted its position in USANA Health Sciences by 1.9% in the 4th quarter. Renaissance Technologies LLC now owns 1,147,323 shares of the company’s stock valued at $22,522,000 after buying an additional 21,793 shares during the last quarter. Vanguard Group Inc. boosted its position in USANA Health Sciences by 5.7% in the 3rd quarter. Vanguard Group Inc. now owns 1,069,032 shares of the company’s stock valued at $29,452,000 after buying an additional 57,249 shares during the last quarter. Finally, Dimensional Fund Advisors LP grew its stake in shares of USANA Health Sciences by 1.9% during the third quarter. Dimensional Fund Advisors LP now owns 915,049 shares of the company’s stock valued at $25,210,000 after acquiring an additional 17,318 shares in the last quarter. 54.25% of the stock is owned by institutional investors and hedge funds.

Key Headlines Impacting USANA Health Sciences

Here are the key news stories impacting USANA Health Sciences this week:

• Positive Sentiment: Sidoti raised its EPS forecasts for Q3 2026 to $0.11 from $0.09, Q1 2027 to $0.34 from $0.31, and Q2 2027 to $0.46 from $0.43. These upward revisions may be supporting a short-term rebound by suggesting analysts see potential earnings improvement beyond the current quarter. MarketBeat USANA analyst estimates
• Neutral Sentiment: Analyst sentiment has become mixed: Sidoti raised select forward estimates, while other analysts lowered near-term expectations. Investors may view the conflicting forecasts as a sign of uncertainty regarding USANA’s recovery.
• Negative Sentiment: USANA’s second-quarter earnings were far below expectations, and revenue also missed forecasts. The company now expects a full-year loss, a major deterioration from earlier expectations and the primary reason the stock has been under pressure this week. Why USANA Health Sciences Stock Plummeted This Week
• Negative Sentiment: An analyst reduced the estimate for USANA’s third-quarter EPS, indicating weaker expected profitability following the earnings miss. Q3 EPS Estimate for USANA Health Sciences Cut by Analyst
• Negative Sentiment: Zacks Research downgraded USANA from “hold” to “strong sell,” adding to the bearish analyst sentiment. Wall Street Zen also lowered its rating, reinforcing concerns about the company’s earnings outlook. Zacks Research

USANA Health Sciences Company Profile

USANA Health Sciences, Inc is a Utah?based company that develops, manufactures and distributes nutritional supplements and personal care products through a network of independent distributors. Founded in 1992 by Dr. Myron Wentz, the company’s portfolio includes vitamins, minerals, dietary supplements, weight?management products and skin?care formulations. USANA’s products are formulated in its own laboratories to meet pharmaceutical?grade standards, and the company has invested heavily in research and development and quality control to support its offerings.

Operating primarily through a direct selling model, USANA serves markets in North America, Asia Pacific, Europe and Latin America.